Business
Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology
Pre-clinical and clinical data demonstrate synergies between pelareorep and the proteasome i...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of HematologyPre-clinical and clinical data demonstrate synergies between pelareorep and the proteasome inhibitor carfilzomib through inflammation, apoptosis and tumor responsesData provides scientific rationale supporting the ongoing phase 1b trial in multiple myeloma patientsSAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 9, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a poster presentation was given over the weekend highlighting pre-clinical and clinical results of combining pelareorep with the proteasome inhibitor carfilzomib in the treatment of multiple myeloma. The presentation was given on Saturday, December 7 as part of the 2019 American Society of Hematology Annual Meeting & Exhibition.The poster, titled, \"Carfilzomib Impairs the Innate Antiviral Immune Response and promotes cytotoxic T-cell Expansion in Oncolytic Virus Treated Multiple Myeloma Patients\" describes synergies between proteasome inhibitors and pelareorep concerning immune cell changes and response in myeloma patients.\"These findings demonstrate that pelareorep, in combination with carfilzomib, infects multiple myeloma cells, thereby providing a strong scientific rationale regarding immune cell changes,\" said Dr. Rita Laeufle, Chief Medical Officer at Oncolytics Biotech. \"The combination of carfilzomib and pelareorep promotes expansion of killer T cells in patients on an ongoing phase 1b study and how it may lead to tumor response when pelareorep is combined with proteasome inhibitors. We are confident that pelareorep could add significant clinical value to the treatment of multiple myeloma patients with the combination of these agents. Our first data in patients from an ongoing study has been very encouraging and further data will be presented at subsequent clinical conferences.\"Key data and conclusions:Demonstrated that pelareorep treatment selectively infected multiple myeloma cells and not normal bone marrow cellsCarfilzomib enhances reovirus entry, infection, and killing of multiple myeloma cellsReovirus significantly increases the frequency and activation of certain killer T cells, ...